Unsurprisingly, rates of heart failure medication utilization—including ACE-inhibitors, angiotensin receptor blockers, and beta blockers—were higher in the NICM cohort; further studies are needed to better assess the impact of modern heart failure therapies on microvascular function in NICM. Here, ACE is linked to heart failure.